We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $479M
1-Year Est. Return 140.7%
This Fund
S&P 500
This Quarter Est. Return
-2.44%
1 Year Est. Return
+140.7%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$411M
AUM Growth
-$46M
Cap. Flow
-$1.26M
Cap. Flow %
-0.31%
Top 10 Hldgs %
68.26%
Holding
46
New
13
Increased
7
Reduced
7
Closed
9

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$24.5M
2
LLY icon
Eli Lilly
LLY
+$19.7M
3
INSP icon
Inspire Medical Systems
INSP
+$15.5M
4
BDX icon
Becton Dickinson
BDX
+$12.8M
5
VCYT icon
Veracyte
VCYT
+$10.4M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$28.2M
2
BPMC
Blueprint Medicines
BPMC
+$24.8M
3
NVST icon
Envista
NVST
+$19.7M
4
EXAS
Exact Sciences
EXAS
+$17.4M
5
MASI
Masimo
MASI
+$14.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDX icon
1
Becton Dickinson
BDX
$44.1B
$46.7M 11.36%
203,965
+55,350
+37% +$12.8M
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$33.5M 8.14%
758,533
-6,135
-0.8% -$282K
BBIO icon
3
BridgeBio Pharma
BBIO
$16.5B
$33.3M 8.1%
962,883
+64,425
+7% +$2.17M
EW icon
4
Edwards Lifesciences
EW
$48.1B
$31.6M 7.68%
435,588
+102,444
+31% +$7.33M
ASND icon
5
Ascendis Pharma A/S
ASND
$16.7B
$30.5M 7.41%
195,523
-20,064
-9% -$2.87M
CYTK icon
6
Cytokinetics
CYTK
$10.9B
$23.5M 5.73%
585,812
+128,225
+28% +$5.89M
VCYT icon
7
Veracyte
VCYT
$4.46B
$22.6M 5.5%
762,225
+271,678
+55% +$10.4M
SNDX icon
8
Syndax Pharmaceuticals
SNDX
$1.86B
$21.3M 5.18%
+1,733,701
New +$24.5M
LLY icon
9
Eli Lilly
LLY
$1.07T
$19.6M 4.76%
+23,682
New +$19.7M
ISRG icon
10
Intuitive Surgical
ISRG
$128B
$18.1M 4.4%
36,499
-411
-1% -$227K
LIVN icon
11
LivaNova
LIVN
$4.4B
$15M 3.65%
381,648
-130,799
-26% -$5.87M
DNTH icon
12
Dianthus Therapeutics
DNTH
$5.72B
$13.8M 3.37%
763,471
– –
INSP icon
13
Inspire Medical Systems
INSP
$1.47B
$13.7M 3.33%
+85,877
New +$15.5M
GPCR icon
14
Structure Therapeutics
GPCR
$3.5B
$12.2M 2.97%
704,864
+135,469
+24% +$3.32M
SLNO
15
DELISTED
Soleno Therapeutics
SLNO
$11.5M 2.8%
+160,962
New +$7.84M
QURE icon
16
uniQure
QURE
$2.64B
$8.8M 2.14%
830,325
-71,648
-8% -$1M
REGN icon
17
Regeneron Pharmaceuticals
REGN
$70.6B
$7.78M 1.89%
+12,261
New +$8.43M
SLNO
18
CALL
DELISTED
Soleno Therapeutics
SLNO
$6.5M 1.58%
+100,000
New +$4.87M
SEPN
19
Septerna Inc
SEPN
$1.51B
$5.93M 1.44%
1,024,245
– –
TARA icon
20
Protara Therapeutics
TARA
$227M
$4.64M 1.13%
1,088,691
– –
ADPT icon
21
Adaptive Biotechnologies
ADPT
$3.57B
$4.54M 1.11%
+611,639
New +$4.7M
MLTX icon
22
MoonLake Immunotherapeutics
MLTX
$1.65B
$4.48M 1.09%
+114,616
New +$4.94M
KROS icon
23
Keros Therapeutics
KROS
$204M
$3.97M 0.97%
389,384
-17,908
-4% -$208K
VIR icon
24
Vir Biotechnology
VIR
$1.5B
$3.96M 0.96%
+611,608
New +$5.44M
REPL icon
25
Replimune Group
REPL
$723M
$3.47M 0.84%
+355,640
New +$4.4M
1
2

Similar funds

FFG
Frisch Financial Group Melville, New York $478M AUM 16.28% 1-Year Est. Return
RFWA
RPg Family Wealth Advisory Burlington, Massachusetts $479M AUM 25.83% 1-Year Est. Return
SWM
Silverlake Wealth Management Williston, Vermont $479M AUM 17.75% 1-Year Est. Return
CMI
Clare Market Investments Dallas, Texas $478M AUM
TCM
Towneley Capital Management Laguna Hills, California $478M AUM 16.21% 1-Year Est. Return
LIM
Longfellow Investment Management Boston, Massachusetts $480M AUM 8% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return
YLHM
Yelin Lapidot Holdings Management Tel Aviv, Israel $480M AUM 42.17% 1-Year Est. Return

Catalio Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Catalio Capital Management held 46 positions worth $411M, down 10% from $457M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Catalio Capital Management's Q1 2025 filing shows 13 new, 7 increased, 7 reduced and 9 closed positions. Its largest new stake was Syndax Pharmaceuticals: 1,733,701 shares worth $21.3M. The largest sale was Bristol-Myers Squibb, an estimated $28.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

  • Catalio Capital Management's largest Q1 2025 buy was Syndax Pharmaceuticals: 1,733,701 shares worth $21.3M.
  • Catalio Capital Management added most to Becton Dickinson in Q1 2025, an estimated $12.8M increase.
  • Catalio Capital Management's biggest Q1 2025 reduction was LivaNova, cutting an estimated $5.87M.
  • Catalio Capital Management fully exited Bristol-Myers Squibb in Q1 2025, selling an estimated $28.2M.
  • Catalio Capital Management's ten largest holdings make up 68% of its $411M portfolio in Q1 2025.
  • Catalio Capital Management opened 13 new positions and closed 9 in Q1 2025.
  • Catalio Capital Management's portfolio value fell 10% quarter-over-quarter to $411M.

Based on Catalio Capital Management's 13F filing for Q1 2025, filed 15 May 2025.